Chemomab Therapeutics (CMMB) Notes Payables (2018 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Notes Payables came in at $9.2 million in Q3 2019, up 387.56% quarter-over-quarter from $1.9 million in Q2 2019.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Notes Payables (2018 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Notes Payables for 2 consecutive years, with $9.2 million the latest figure, recorded in Q3 2019.
- For the quarter ending Q3 2019, Notes Payables changed N/A year-over-year to $9.2 million; the trailing twelve-month figure through Sep 2019 stood at $9.2 million (changed N/A YoY), and the FY2018 full-year result was $7.0 million, changed N/A from the prior year.
- Notes Payables grew to $9.2 million in Q3 2019 per CMMB's latest filing, from $1.9 million in the prior quarter.
- Across five years, Notes Payables topped out at $9.2 million in Q3 2019 and bottomed at $1.9 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Chemomab Therapeutics | 19.49 Mn | 19.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 9.17 Mn |
| Jun 30, 2019 | 1.88 Mn |
| Dec 31, 2018 | 6.98 Mn |